Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
In hidradenitis suppurativa, 72% of patients on the highest dose of tulisokibart achieved at least a 50% reduction in inflammatory skin lesions after 16 weeks versus 35% on placebo. Up to 41% achieved at least a 75% reduction versus 15% on placebo, and safety was comparable.
The drug was tested in patients with moderate-to-severe hidradenitis suppurativa, a chronic skin disease.
Merck NYSE:MRK said on Wednesday its experimental drug met the main goal of a mid-stage study in patients with moderate-to-severe hidradenitis suppurativa, a chronic skin disease that causes painful lumps, abscesses and scarring.